NCT06125756View on ClinicalTrials.gov

Safety and Efficacy Clinical Study of Severe Hemophilia B Treatment With KL001

EARLY_PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

December 20, 2023

Primary Completion Date

September 20, 2024

Study Completion Date

October 30, 2025

Conditions
Hemophilia B Without Inhibitor
Interventions
DRUG

Low dose KL001

Subjects will be dosed with single dose of KL001 at 2.5x10\^12 vg/kg.

DRUG

Middle dose KL001

Subjects will be dosed with single dose of KL001 at 5.0x10\^12 vg/kg.

DRUG

High dose KL001

Subjects will be dosed with single dose of KL001 at 1.0x10\^13 vg/kg.

All Listed Sponsors
lead

Affiliated Hospital of Guangdong Medical University

OTHER

NCT06125756 - Safety and Efficacy Clinical Study of Severe Hemophilia B Treatment With KL001 | Biotech Hunter | Biotech Hunter